Combinational effect of angiotensin receptor blocker and folic acid therapy on uric acid and creatinine level in hyperhomocysteinemia-associated hypertension by Singh, Yogendra et al.
  
 
This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1002/bab.1799. 
 
This article is protected by copyright. All rights reserved. 
 
Combinational Effect of Angiotensin Receptor Blocker and Folic Acid Therapy on Uric 
Acid and Creatinine Level in Hyperhomocysteinemia Associated Hypertension 
Yogendra Singh
1
, Vijaya Paul Samuel
2
, Sunita Dahiya
3
, Gaurav Gupta
4
, Ritu Gillhotra
4
, 
Anurag Mishra
4
, Mahaveer Singh
5
, Nagaraja SreeHarsha
6
, Shiva Kumar Gubbiyappa
7
, 
Murtaza M. Tambuwala
8
, Dinesh Kumar Chellappan
9
, Kamal Dua 
10,11
 
1. Department of pharmaceutical sciences, Mahatma Gandhi College of Pharmaceutical 
Sciences, Sitapura, Jaipur, India 
2. Department of Anatomy, RAK College of Medicine, RAK Medical and Health 
Sciences, University, Ras Al Khaimah, UAE 
3. Department of Pharmaceutical Sciences, School of Pharmacy, University of Puerto 
Rico, Medical Sciences Campus,  San Juan, Puerto Rico, USA 
4. School of Pharmacy, Suresh Gyan Vihar University, Jagatpura, Mahal Road, Jaipur, 
India 
5. School of Pharmaceutical Sciences, Jaipur National University, Jagatpura, Jaipur, 
India 
6. Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal 
University, Al-Ahsa, Saudi Arabia 
7. School of Pharmacy, GITAM University, Hyderabad, India 
8. School of Pharmacy & Pharmaceutical Sciences, Ulster University, Coleraine, County 
Londonderry, Northern Ireland, United Kingdom 
9. Department of Life Sciences, International Medical University, Kuala Lumpur, 
Malaysia 57000 
10. Discipline of Pharmacy, Graduate School of Health, University of Technology 
Sydney, Sydney, NSW 2007, Australia 
11. Priority Research Centre for Healthy Lungs, School of Biomedical Sciences and 
Pharmacy, The University of Newcastle, Callaghan, Australia 
 
Corresponding Author:  
  
 
This article is protected by copyright. All rights reserved. 
 
1. Yogendra Singh, Department of pharmaceutical sciences, Mahatma Gandhi College 
of Pharmaceutical Sciences, Sitapura, Jaipur, India.  
Email Id: yogendra.singh119@gmail.com 
2. Gaurav Gupta, School of Pharmaceutical Sciences, Jaipur National University, 
Jagatpura 302017, Jaipur, India.  
Email Id: gauravpharma25@gmail.com 
 
 
 
 
Abstract 
Homocysteine [HSCH2CH2CH(NH2)COOH] (Hcy), is a sulfur-containing amino acid of 
135.18 Da of molecular weight, generated during conversion of methionine to cysteine. If 
there is a higher accumulation of Hcy in the blood, i.e. usually above 15 μmol/L, it leads to a 
condition referred to as hyperhomocysteinemia. A meta-analysis of observational study 
suggested an elevated concentration of Hcy in blood, which is termed as the risk factors 
leading to ischemic heart disease (IHD) and stroke. Further experimental studies stated that Hcy 
can lead to an increase in the proliferation of vascular smooth muscle cells and functional 
impairment of endothelial cells. The analyses confirmed some of the predictors for Hcy 
presence, such as serum uric acid (UA), systolic blood pressure, and hematocrit. However, 
angiotensin-converting enzyme inhibitors Angiotensin-converting enzyme (ACE) inhibitors 
and angiotensin converting enzyme inhibitors (ARBs) (except losartan) alone are inadequate 
for controlling UA and creatinine level, although the addition of folic acid may be beneficial 
in hypertensive patients who are known to have a high prevalence of elevated Hcy. We 
hypothesized that combination therapy with an ARB (olmesartan) and folic acid is a 
  
 
This article is protected by copyright. All rights reserved. 
 
promising treatment for lowering the UA and creatinine level in hyperhomocysteinemia 
associated hypertension. 
Keywords: Homocysteine, hyperhomocysteinemia, hypertension, creatinine, angiotensin 
receptor blocker, folic acid 
Highlights  
1. Higher accumulation of Homocysteine in the blood leads to a hyperhomocysteinemia. 
2. Folic acid is a good candidate as a supplement for treating the hyperhomocysteinemia 
associated hypertension. 
3. Folic acid does not affect the function of normal cell. 
 
Introduction 
Hcy was identified in 1932 by Butz and du Vigneaud at the University of Illinois as an amino 
acid of biological importance [1]. Mudd et. al. in 1964 for the first time identified the enzyme 
defects in cystathionine β synthase causing homocystinuria [2]. A study in 1969 stated the 
role played by a high level of Hcy in causing atherosclerosis through deposition of fibrin, 
oxidant stress, the release of cytokine, inflammation and other related mechanisms [3-5].  
Synthesis of Homocysteine 
In the synthesis of Hcy, methionine (has a methyl group attached with a sulfur atom) is 
converted to S−Adenosyl Methionine (SAMe), in the presence of methionine 
adenosyltransferase (MAT) and ATP with the addition of adenosine to the sulfur which 
activates the methyl group [6]. Removing the methyl group from SAMe leads to the 
formation of SAH (S−Adenosyl Hcy). Further, in the presence of a hydrolase enzyme, SAh is 
converted to Hcy by adenosine removal [7] (Figure 1).  
Metabolism of Homocysteine 
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Metabolism of Hcy is carried out in three different ways: 
1) In liver cells, the transsulfuration pathway is catalyzed by Vitamin B6, which leads to 
the conversion of Hcy (around 60%) to cysteine (Cys). Cys can be used as building 
blocks for many proteins that can be used in the formation of glutathione (GSH), 
which is an anti-oxidant or oxidized to form the taurine (an amino acid) [8, 9]. 
2) Hcy can also be reconverted to Met through the addition of a methyl group. The 
methyl group can be added in the presence of methionine synthase enzyme and vit. 
B12, where methylated folic acid (Methyltetrahydrofolate, MTHF) acts as the methyl 
group donor [10-13]. 
3) In another liver pathway, choline is converted to betaine (TMG), which acts as the 
methyl group donor [14, 15] 
The prevalence of hyperhomocysteinemia in India varies from 52%-84% which is caused due 
to elevated levels of Hyc [16, 17].In the case of fasting, the total plasma concentration of Hcy 
seemed to be low, i.e. 5-15 μmol/L using HPLC techniques, in case of healthy humans.  
Application of immunoassay techniques for the determination of levels of Hcy yielded 5-
12 μmol/L concentration [18]. A concentration level higher than 100 μmol/L leads to severe 
severe hyperhomocysteinemia, whereas 16-30 μmol/L of Hcy leads to moderate condition 
and a value between 31-100 μmol/L leads to the intermediate condition [19-21]. 
Elevated Hcy levels are connected with various pathologies both in adults and children. 
Causes of high Hcy concentration include genetic mutations in 5, 10-
methylenetetrahydrofolate reductase (MTHFR) and enzyme deficiencies of methionine 
synthase (MS) and cystathionine β-synthase (CβS) (21-23). 
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Homocysteine Associated cardiovascular problem  
All forms of hypertension related to high systolic and diastolic pressure as well as high pulse 
pressure, have been treated as recognizable and independent risk factors for determination of 
cardiovascular morbidity and mortality. For reducing such risk factors, anti-hypertensive 
treatment needs to be adopted that uses anti-hypersensitive agents, alone or in combination 
[22]. Furthermore, Hyc as an independent risk factor leading to cardiovascular modalities, 
due to the increase in the oxidative stress [23-25]. 
Some of the population-based studies have stated a direct interlinking between the levels of 
Hcy with blood pressure, especially systolic. A previous study stated that the increase in 
plasma Hcy concentration by 5 μmol/L leads to an increase in the blood pressure by 0.7/0.5 
mmHg and 1.2/0.7 mmHg, in men and women, respectively. A meta-analysis study in an 
observational study suggested that an elevated level of total blood Hyc concentrations are 
associated with the risk of IHD and stroke [26-28]. With every 3 μmol/L elevation in the 
level of Hcy, the risk of IHD increased by around 11% and that of stroke increased by around 
19% [29]. 
Arteriolar constriction  
The structure, as well as functionality of arteries, are affected by high levels of Hcy. As 
mentioned earlier, the proliferation of vascular smooth muscle cell and impairment of 
endothelial function can be an after-effect of increased Hcy concentration [30, 31], thus 
leading to increased arteriolar constriction as well as peripheral resistance. It may also lead to 
an increase in the blood pressure by elevating the total peripheral resistance, especially by 
small resistant arterioles and arteries [32-34].  
Insulin Resistance: 
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The increased resistance of insulin (hyperinsulinemia) associated with clinical manifestation 
of hyperhomocysteinemia elevated blood pressure. The condition of hyperinsulinemia may 
lead to an increase in the level of Hcy as well as elevate blood pressure through various 
mechanisms. On the contrary, factors like dietary habits also contribute to insulin resistance 
[35-37]. In summary, metabolic disturbances and long-term hyperhomocysteinemia together 
with vascular remodeling suggested that enhanced oxidative stress, endothelium dysfunction, 
and decreased PPARγ expression in the vessel wall could be underlying mechanisms for 
hyperhomocysteinemia associated hypertension [38].  
Hyperuricemia and creatinine  
Hyperuricemia leads to urate crystal deposition in between the joints, thus becoming a prime 
risk factor in the development of gout [39]. In addition to this, it also leads to other clinical 
diseases, such as cardiovascular and cerebrovascular conditions. Elevated concentration of 
UA is linked to increased rates of cardiovascular (CV) morbidity and mortality, stroke, 
chronic kidney disease, metabolic syndrome, and hypertension in the general population [40-
49]. Multivariate analysis study was conducted to detect that systolic blood pressure, UA, and 
hematocrit are the predictors for increased Hcy concentration, [50-52]. Moreover, the various 
study explores significant correlations between Hcy, uric acid, and creatinine [53, 54]. 
Arrhythmias  
Slightly enhance the micromolar concentration of Hcy between 50-500 micromole/Liter in 
the blood leads to inhibition of cardiac Na
+
 and K
+
 channels and transient outward current 
which prolongs the action potential and change in electrophysiologic properties of the heart 
[55-57]. 
Effect of ACE inhibitors and ARBs in hyperhomocysteinemia associated hypertension  
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The vasodilatory property of RAAS inhibitor candidates, like ACE inhibitors and ARBs 
and have found to reduce the risk of CV disease via oxidative stress management [58]. 
However, ACEIs drugs like enalapril have been found to be non-effective in controlling 
the blood pressure in the presence of Hcy ≥15 μmol/L [59-61].  On the other hand, a 
randomized study on ACE inhibitor like captopril has statistically insignificant effects on 
tHcy after 4 weeks or creatinine [62] while Enalapril may also increase in plasma tHcy 
among the hypertensive patients[63]. Moreover, the treatment group receiving enalapril 
significantly increase the serum uric acid concentration and [64] which is an independent risk 
factor for oxidative stress, stroke/ transient ischemic attack at the value ≥  6.35 mg/dl[65]. 
However, ACEIs inhibit the synthesis of biologically active peptide Angiotensin II by 
blocking the ACE but the synthesis of AngII resumed due to activation of a non-ACE 
pathway that will be mediated in the presence of chymase, kallikrein, cathepsin G, and 
elastase-2 enzyme[66]. Hence, the oxidative stress is enhanced by activation of the AT1 
receptor [67-69]. 
 A recent animal study shows that mild to moderate increase in Hcy concentration leads to 
increase expression and binding and of AT1 Receptor that mediated vascular injury [70, 71]. 
A previous study showed no significant change in the levels of plasma Hcy in hypertensive 
patients administered with Olmesartan [72-74]. However, when these patients were treated 
with either candesartan or amlodipine, at least 2 μmol l−1 increase in Hcy concentration 
was observed in the study patients [75-77]. Moreover, ARBs increase the level of serum 
creatinine and uric acid (except Losartan) because losartan inhibits URAT1, a major 
transporter in the kidney for uric acid reabsorption while other ARBs does not do it at 
therapeutic concentration [78-84]. 
Folic acid  
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Folate is an essential element required in synthesis of pyrimidine, purine (precursors of DNA 
and RNA, respectively) and amino acid metabolism including Hcy. Deficiency of folate 
results in increasing the risk of getting hyperhomocysteinemia [85, 86]. 
However, ACE inhibitors and ARBs (except losartan) alone are inadequate for controlling 
UA and creatinine level, although the addition of folic acid may be beneficial, in hypertensive 
patients who are known to have a high prevalence of elevated homocysteine (Hcy)[87-90]. 
Conventional hyper uric acid therapies aim at either reducing UA production using xanthine 
oxidase (XO) inhibitors, such as allopurinol, or increasing renal UA excretion with drugs, 
such as benzene bromide malone and probenecid. However, these agents can effectively 
lower the serum UA levels but they do have a number of side effects, including allergic 
reactions, liver damage, kidney damage, bone marrow suppression and gastrointestinal 
symptoms [91-93]. Thus, we need safe and effective therapeutic approaches. Hence fore, 
Folic acid is several folds more potent as an inhibitor of Xanthine oxidase than the know 
inhibitor allopurinol, which results decrease the level of uric acid [94, 95].  
 
Conclusion: 
In the clinical setting, RAAS inhibitor is the first choice of drug for the treatment of 
hypertension by medical practitioners but the determination of homocysteine level is not very 
frequent for diagnosis of hypertension in adults and geriatric patients that may arise certain 
blood pressure related consequences. So, folic acid could be a good candidate as a 
supplement for treating the hyperhomocysteinemia associated hypertension. Moreover, folic 
acid does not affect the function of normal cell i.e could be used as nutrients and growth 
supplement for damage cell due to oxidative stress. 
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Most of the previous studies also demonstrated that use of folic acid (0.4 mg/day) 
supplementation failed to lower blood Hcy, uric acid and creatinine level, while high dose 
1000 mg does not significantly lower the uric acid concentration. Contradictions in the study 
outcomes might be due to small sample size and differences in population characteristics, for 
example, patients treated with or without folate supplementation. 
 Thus, as a future perspective, we need to establish an adequate dose of folic acid as a 
supplement with ARB like Olmesartan for the treatment of hyperhomocysteinemia associated 
hypertension. 
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